T Cell News and Research

Latest T Cell News and Research

Study finds massive blood transfusion associated with severe complications

A study presented at this year's American Society of Anesthesiologists Annual Meeting indicates that massive blood transfusion is associated with a significant increase in perioperative risk for mortality, cardiopulmonary complications, and wound-related and infectious complications in the long term.

20 Oct 2010

First in vivo screening system for complete human nuclear hormone receptor family

The InDanio screening system can be used, for example, to functionally characterize 'orphan' receptors - those for which their natural ligands or specific function are unknown - and thus qualify them as potential targets for drug discovery. The system can also be used to screen compound libraries in order to identify and refine potential new drugs that target NR proteins.

20 Oct 2010

New approaches to explore causes of autoimmunity and immune deficiency diseases

A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.

20 Oct 2010

Study reveals how cells crank up cancer activators

A new technique that searches blood for the tiniest remnants of broken down proteins has revealed new information about how cells crank up cancer activators called proteases. The results improve researchers' understanding of the mechanics of breast cancer and point to where to look for possible indicators of early disease.

20 Oct 2010

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Curcumin, the major component in the spice turmeric, when combined with the drug Cisplatin enhances the chemotherapy's suppression of head and neck cancer cell growth, researchers with UCLA's Jonsson Cancer Center have found.

20 Oct 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Vitro signs contract with HemoGenix to manufacture, distribute stem cell analysis tools

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.

20 Oct 2010

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims related to the therapeutic application of let-7 in the regulation of oncogenes. The claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the pioneering work of Dr. Frank Slack, Professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT.

20 Oct 2010

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably when the molecular mechanisms that keep them in check go awry.

20 Oct 2010

New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study

Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.

20 Oct 2010

Cell Therapeutics enters agreement to sell $21.0 million of Series 7 Preferred Stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $21.0 million of shares of its Series 7 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to four institutional investors.

20 Oct 2010

Japanese study finds proton beam therapy safe and effective for Stage I inoperable NSCLC

Proton beam therapy is safe and effective and may be superior to other conventional treatments for Stage I inoperable non-small cell lung cancer (NSCLC) patients, according to a study in the October issue of the International Journal of Radiation Oncology•Biology•Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

20 Oct 2010

NHLBI launches multicenter study of body cooling treatment in infants and children after cardiac arrest

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has launched the first large-scale, multicenter study to investigate the effectiveness of body cooling treatment in infants and children who have had cardiac arrest. The Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials total more than $21 million over six years.

20 Oct 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

ThermoGenesis enters licensing agreement with BioParadox for Res-Q technology

ThermoGenesis Corp. a leading supplier of innovative products and services that process and store adult stem cells, said today it has entered into a license and distribution agreement for its Res-Q 60 BMC (Res-Q) System with BioParadox, Inc., a newly-formed regenerative medicine company focusing on point-of-care cardiovascular therapies.

20 Oct 2010

Protein hormone inhibits leptin-induced migration of liver cancer cells

A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.

19 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Pharmacy graduate awarded national recognition for pioneering research in genetics

A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

T Cell News and Research

Latest T Cell News and Research

Study finds massive blood transfusion associated with severe complications

First in vivo screening system for complete human nuclear hormone receptor family

New approaches to explore causes of autoimmunity and immune deficiency diseases

Study reveals how cells crank up cancer activators

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Nitric oxide inhalation reduces pain in sickle cell disease patients

Vitro signs contract with HemoGenix to manufacture, distribute stem cell analysis tools

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study

Cell Therapeutics enters agreement to sell $21.0 million of Series 7 Preferred Stock

Japanese study finds proton beam therapy safe and effective for Stage I inoperable NSCLC

NHLBI launches multicenter study of body cooling treatment in infants and children after cardiac arrest

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

ThermoGenesis enters licensing agreement with BioParadox for Res-Q technology

Protein hormone inhibits leptin-induced migration of liver cancer cells

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Pharmacy graduate awarded national recognition for pioneering research in genetics

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in